CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Eplerenone +1 moredrug
Likely dose
Eplerenone 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01394627
NCT01394627N/ACompleted
CompareCT.gov

Hypoglycemia and the Mineralocorticoid Receptor

Brigham and Women's Hospital·interventional·Posted Jul 14, 2011·Updated Nov 17, 2017

In Brief

A clinical study evaluating Eplerenone and Placebo for Hypoglycemia. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia
CountriesUnited States
CollaboratorsRobert Wood Johnson Foundation, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 14, 2011
Enrollment StartJan 1, 2011
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.0 years ago

Interventions

Eplerenonedrug

100mg x 2

Placebodrug